Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on February 9, 2023. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The filing reports on a material definitive agreement entered into on the same date.
Key Financial Metrics and Agreements
The filing details a financing arrangement rather than standard operational financial metrics such as revenue or profit.
- Agreement Type: Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited.
- Additional Credit Facility: Up to $2,000,000 available for borrowing.
- Draw Limit: Maximum of $1,000,000 per single draw, subject to lender discretion.
- Availability Period: Until May 9, 2023.
- Repayment Date: February 14, 2024.
- Security: Obligations are secured by a security interest in AgeX assets under a February 14, 2022 Security Agreement.
- Conversion Features: The note includes provisions for converting the loan balance and accrued fees into AgeX common stock, as well as the issuance of common stock purchase warrants.
Material Changes Versus Prior Period
This filing represents an amendment to a Secured Convertible Promissory Note originally dated February 14, 2022. The primary material change is the expansion of the credit facility by an additional $2,000,000. All other material provisions of the original note, including loan origination fees, default provisions, and conversion rights, remain in effect and apply to the new credit availability.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the company's plans and expectations, noting that actual results may differ materially due to various risk factors detailed in periodic SEC reports. The company disclaims any obligation to update these statements. No specific operational guidance or financial outlook beyond the terms of the note was provided in this document.
Investor Verification Checklist
- Verify the total outstanding principal balance under the original February 2022 note prior to any new draws.
- Review the specific terms of the conversion price and warrant exercise price in the full text of the Amended Note (Exhibit 10.1).
- Confirm the impact of the additional debt on the company's current liquidity position and cash runway.
- Examine the "Risk Factors" section in the company's most recent 10-K or 10-Q for details on the risks associated with convertible debt and potential dilution.